Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus.
Cole S, Walsh A, Yin X, Wechalekar MD, Smith MD, Proudman SM, Veale DJ, Fearon U, Pitzalis C, Humby F, Bombardieri M, Axel A, Adams H 3rd, Chiu C, Sharp M, Alvarez J, Anderson I, Madakamutil L, Nagpal S, Guo Y.
Cole S, et al. Among authors: humby f.
Arthritis Res Ther. 2018 May 2;20(1):85. doi: 10.1186/s13075-018-1578-z.
Arthritis Res Ther. 2018.
PMID: 29720240
Free PMC article.